These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 16257852)
1. Evaluation of the carcinogenic potential of clofibrate in the FVB/Tg.AC mouse after dermal application--part II. Torrey CE; Wall HG; Campbell JA; Kwanyuen P; Hoivik DJ; Miller RT; Allen JS; Jayo MJ; Selinger K; Santostefano MJ Int J Toxicol; 2005; 24(5):327-39. PubMed ID: 16257852 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of the carcinogenic potential of clofibrate in the FVB/Tg.AC mouse after oral administration--part I. Torrey CE; Wall HG; Campbell JA; Kwanyuen P; Hoivik DJ; Miller RT; Allen JS; Jayo MJ; Selinger K; Savina PM; Santostefano MJ Int J Toxicol; 2005; 24(5):313-25. PubMed ID: 16257851 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of the carcinogenic potential of clofibrate in the rasH2 mouse. Nesfield SR; Clarke CJ; Hoivik DJ; Miller RT; Allen JS; Selinger K; Santostefano MJ Int J Toxicol; 2005; 24(5):301-11. PubMed ID: 16257850 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the carcinogenic potential of clofibrate in the p53+/- mouse. Torrey CE; Campbell JA; Hoivik DJ; Miller RT; Allen JS; Mann PC; Selinger K; Rickert D; Savina PM; Santostefano MJ Int J Toxicol; 2005; 24(5):289-99. PubMed ID: 16257849 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of the carcinogenic potential of clofibrate in the neonatal mouse. Nesfield SR; Williams TC; Hoivik DJ; Miller RT; Allen JS; Selinger K; Rickert D; Santostefano MJ Int J Toxicol; 2005; 24(5):341-8. PubMed ID: 16257853 [TBL] [Abstract][Full Text] [Related]
6. Topical application of representative multifunctional acrylates produced proliferative and inflammatory lesions in F344/N rats and B6C3F1 mice, and squamous cell neoplasms in Tg.AC mice. Doi AM; Hailey JR; Hejtmancik M; Toft JD; Vallant M; Chhabra RS Toxicol Pathol; 2005; 33(6):631-40. PubMed ID: 16176922 [TBL] [Abstract][Full Text] [Related]
7. 26-Week dermal oncogenicity study evaluating pure trans-capsaicin in Tg.AC hemizygous mice (FBV/N). Chanda S; Erexson G; Frost D; Babbar S; Burlew JA; Bley K Int J Toxicol; 2007; 26(2):123-33. PubMed ID: 17454252 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Tg.AC assay: specificity testing with three noncarcinogenic pharmaceuticals that induce selected stress gene promoters in vitro and the inhibitory effects of solvent components. Thompson KL; Rosenzweig BA; Weaver JL; Zhang J; Lin KK; Sistare FD Toxicol Sci; 2003 Aug; 74(2):271-8. PubMed ID: 12773758 [TBL] [Abstract][Full Text] [Related]
9. Hemizygous Tg.AC transgenic mouse as a potential alternative to the two-year mouse carcinogenicity bioassay: evaluation of husbandry and housing factors. Holden HE; Stoll RE; Spalding JW; Tennant RW J Appl Toxicol; 1998; 18(1):19-24. PubMed ID: 9526830 [TBL] [Abstract][Full Text] [Related]
10. Induction of invasive mouse skin carcinomas in transgenic mice with mutations in both H-ras and p53. Zhang Z; Yao R; Li J; Wang Y; Boone CW; Lubet RA; You M Mol Cancer Res; 2005 Oct; 3(10):563-74. PubMed ID: 16254190 [TBL] [Abstract][Full Text] [Related]
11. Oxymetholone: II. Evaluation in the Tg-AC transgenic mouse model for detection of carcinogens. Holden HE; Stoll RE; Blanchard KT Toxicol Pathol; 1999; 27(5):507-12. PubMed ID: 10528629 [TBL] [Abstract][Full Text] [Related]
12. Oral and dermal exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces cutaneous papillomas and squamous cell carcinomas in female hemizygous Tg.AC transgenic mice. Wyde ME; Braen AP; Hejtmancik M; Johnson JD; Toft JD; Blake JC; Cooper SD; Mahler J; Vallant M; Bucher JR; Walker NJ Toxicol Sci; 2004 Nov; 82(1):34-45. PubMed ID: 15282402 [TBL] [Abstract][Full Text] [Related]